Mirtazapina Aurobindo (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Aurobindo, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder and depressive episodes associated with bipolar disorder, and may be employed off‑label for certain anxiety conditions.

GNH USA supplies Mirtazapina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Mirtazapine is used in the management of depressive and related mood disorders. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Bipolar depression: alleviates depressive episodes in individuals with bipolar I or II disorder. - Anxiety disorders (off‑label): may lessen anxiety symptoms in some patients, though use is not formally approved.

Mirtazapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Mood worsening or emergence of suicidal thoughts

When prescribing mirtazapine, clinicians should consider several precautionary measures to ensure safe use. - Monitor weight: patients may experience significant weight gain, requiring periodic assessment. - Assess for suicidal ideation: especially during early treatment or dose changes. - Evaluate hepatic function: dose adjustment may be needed in severe liver impairment. - Caution with CNS depressants: concurrent use can enhance sedation and respiratory depression. - Avoid abrupt discontinuation: taper gradually to reduce risk of withdrawal symptoms. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Mirtazapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can cause hypertensive crisis or serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Other CNS depressants (e.g., benzodiazepines, alcohol): can intensify sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic effect. - Anticoagulants (e.g., warfarin): monitor INR as mirtazapine may affect clotting. - Antihistamines: additive sedative effects may occur.